Stock market investors have enjoyed strong annual returns over the past two years, but analysts caution that 2025 may not ...

AbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s ...

In February 2025, stock markets fell on average. The S&P 500 (SPY) fell by 1.27%, due mostly to a decline in technology stocks. Investors reallocated their holdings into the drug sector. AbbVie (ABBV) ...

EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis: North Chicago, Illinois Monday, March 3, 2025, 15:00 Hrs [IST] AbbVie annou ...

AbbVie, Thermo Fisher Scientific, Recursion Pharmaceuticals, Bloom Energy, and Iovance Biotherapeutics are the five Biotech ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...

The treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

JAK inhibitor Rinvoq (upadacitinib) has been backed by the CHMP as a 15mg, once-daily treatment for adults with GCA, an ...

AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with ...

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib ...